APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hereditary Angioedema Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hereditary Angioedema Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025187 pages

Choose your research edition.

Industry ResearchHereditary Angioedema Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hereditary Angioedema Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Hereditary Angioedema Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hereditary Angioedema Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hereditary Angioedema Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Hereditary Angioedema Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hereditary Angioedema Drug include Takeda, Pharming Group NV, Ionis Pharmaceuticals, Inc., IBio Inc., CSL Limited and BioCryst Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hereditary Angioedema Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hereditary Angioedema Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hereditary Angioedema Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hereditary Angioedema Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hereditary Angioedema Drug Segment by Company

Takeda

Pharming Group NV

Ionis Pharmaceuticals, Inc.

IBio Inc.

CSL Limited

BioCryst Pharmaceuticals, Inc.

Hereditary Angioedema Drug Segment by Type

C1 Esterase Inhibitor

Kallikrein Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Hereditary Angioedema Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hereditary Angioedema Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hereditary Angioedema Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hereditary Angioedema Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hereditary Angioedema Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hereditary Angioedema Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hereditary Angioedema Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hereditary Angioedema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hereditary Angioedema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hereditary Angioedema Drug Industry Trends Table 2. Hereditary Angioedema Drug Industry Drivers Table 3. Hereditary Angioedema Drug Industry Opportunities and Challenges Table 4. Hereditary Angioedema Drug Industry Restraints Table 5. Global Hereditary Angioedema Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hereditary Angioedema Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hereditary Angioedema Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Hereditary Angioedema Drug Sales Market Share by Manufacturers Table 9. Global Hereditary Angioedema Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Hereditary Angioedema Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hereditary Angioedema Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hereditary Angioedema Drug Manufacturers, Product Type & Application Table 13. Global Hereditary Angioedema Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hereditary Angioedema Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of C1 Esterase Inhibitor Table 17. Major Manufacturers of Kallikrein Inhibitor Table 18. Major Manufacturers of Selective Bradykinin B2 Receptor Antagonist Table 19. Global Hereditary Angioedema Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 21. Global Hereditary Angioedema Drug Sales by Type (2027-2032) & (W Units) Table 22. Global Hereditary Angioedema Drug Sales Market Share by Type (2021-2026) Table 23. Global Hereditary Angioedema Drug Sales Market Share by Type (2027-2032) Table 24. Global Hereditary Angioedema Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Hereditary Angioedema Drug Revenue by Type (2021-2026) & (W Units) Table 26. Global Hereditary Angioedema Drug Revenue by Type (2027-2032) & (W Units) Table 27. Global Hereditary Angioedema Drug Revenue Market Share by Type (2021-2026) Table 28. Global Hereditary Angioedema Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacies Table 30. Major Manufacturers of Online Pharmacies Table 31. Major Manufacturers of Retail Pharmacies Table 32. Global Hereditary Angioedema Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 34. Global Hereditary Angioedema Drug Sales by Application (2027-2032) & (W Units) Table 35. Global Hereditary Angioedema Drug Sales Market Share by Application (2021-2026) Table 36. Global Hereditary Angioedema Drug Sales Market Share by Application (2027-2032) Table 37. Global Hereditary Angioedema Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Hereditary Angioedema Drug Revenue by Application (2021-2026) & (W Units) Table 39. Global Hereditary Angioedema Drug Revenue by Application (2027-2032) & (W Units) Table 40. Global Hereditary Angioedema Drug Revenue Market Share by Application (2021-2026) Table 41. Global Hereditary Angioedema Drug Revenue Market Share by Application (2027-2032) Table 42. Global Hereditary Angioedema Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Hereditary Angioedema Drug Sales by Region (2021-2026) & (W Units) Table 44. Global Hereditary Angioedema Drug Sales Market Share by Region (2021-2026) Table 45. Global Hereditary Angioedema Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 46. Global Hereditary Angioedema Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 48. North America Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 49. North America Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 50. Europe Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. Europe Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 52. Europe Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 53. Asia Pacific Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Asia Pacific Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 55. Asia Pacific Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 56. South America, Middle East and Africa Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. South America, Middle East and Africa Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 58. South America, Middle East and Africa Hereditary Angioedema Drug Sales by Country (2027-2032) & (W Units) Table 59. Global Hereditary Angioedema Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Hereditary Angioedema Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Hereditary Angioedema Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Hereditary Angioedema Drug Revenue Market Share by Region (2021-2026) Table 63. Global Hereditary Angioedema Drug Revenue Market Share by Region (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Hereditary Angioedema Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Takeda Hereditary Angioedema Drug Product Portfolio Table 68. Takeda Recent Development Table 69. Pharming Group NV Company Information Table 70. Pharming Group NV Business Overview Table 71. Pharming Group NV Hereditary Angioedema Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pharming Group NV Hereditary Angioedema Drug Product Portfolio Table 73. Pharming Group NV Recent Development Table 74. Ionis Pharmaceuticals, Inc. Company Information Table 75. Ionis Pharmaceuticals, Inc. Business Overview Table 76. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 78. Ionis Pharmaceuticals, Inc. Recent Development Table 79. IBio Inc. Company Information Table 80. IBio Inc. Business Overview Table 81. IBio Inc. Hereditary Angioedema Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. IBio Inc. Hereditary Angioedema Drug Product Portfolio Table 83. IBio Inc. Recent Development Table 84. CSL Limited Company Information Table 85. CSL Limited Business Overview Table 86. CSL Limited Hereditary Angioedema Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. CSL Limited Hereditary Angioedema Drug Product Portfolio Table 88. CSL Limited Recent Development Table 89. BioCryst Pharmaceuticals, Inc. Company Information Table 90. BioCryst Pharmaceuticals, Inc. Business Overview Table 91. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 93. BioCryst Pharmaceuticals, Inc. Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Hereditary Angioedema Drug Distributors List Table 97. Hereditary Angioedema Drug Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Hereditary Angioedema Drug Product Image Figure 2. Global Hereditary Angioedema Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hereditary Angioedema Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hereditary Angioedema Drug Sales (2021-2032) & (W Units) Figure 5. Global Hereditary Angioedema Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hereditary Angioedema Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. C1 Esterase Inhibitor Image Figure 9. Kallikrein Inhibitor Image Figure 10. Selective Bradykinin B2 Receptor Antagonist Image Figure 11. Global Hereditary Angioedema Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Hereditary Angioedema Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Hereditary Angioedema Drug Sales Market Share by Type (2021-2032) Figure 14. Global Hereditary Angioedema Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Hereditary Angioedema Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Hereditary Angioedema Drug Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacies Image Figure 18. Online Pharmacies Image Figure 19. Retail Pharmacies Image Figure 20. Global Hereditary Angioedema Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Hereditary Angioedema Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Hereditary Angioedema Drug Sales Market Share by Application (2021-2032) Figure 23. Global Hereditary Angioedema Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Hereditary Angioedema Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Hereditary Angioedema Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 27. North America Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Canada Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Mexico Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Europe Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. France Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. U.K. Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Italy Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Netherlands Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Asia Pacific Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 40. China Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Japan Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. South Korea Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Southeast Asia Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. India Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Australia Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South America, Middle East and Africa Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South Africa Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Saudi Arabia Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Turkey Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Argentina Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. UAE Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Egypt Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Chile Hereditary Angioedema Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Global Hereditary Angioedema Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Hereditary Angioedema Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Hereditary Angioedema Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Hereditary Angioedema Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Hereditary Angioedema Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Hereditary Angioedema Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Hereditary Angioedema Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Hereditary Angioedema Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda
  • Pharming Group NV
  • Ionis Pharmaceuticals, Inc.
  • IBio Inc.
  • CSL Limited
  • BioCryst Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hereditary Angioedema Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hereditary Angioedema Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hereditary Angioedema Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hereditary Angioedema Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hereditary Angioedema Drug Market Dynamics
  1. 2.1 Hereditary Angioedema Drug Industry Trends
  2. 2.2 Hereditary Angioedema Drug Industry Drivers
  3. 2.3 Hereditary Angioedema Drug Industry Opportunities and Challenges
  4. 2.4 Hereditary Angioedema Drug Industry Restraints
3 Hereditary Angioedema Drug Market by Manufacturers
  1. 3.1 Global Hereditary Angioedema Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hereditary Angioedema Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hereditary Angioedema Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hereditary Angioedema Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hereditary Angioedema Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hereditary Angioedema Drug Manufacturers, Product Type & Application
  7. 3.7 Global Hereditary Angioedema Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hereditary Angioedema Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hereditary Angioedema Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hereditary Angioedema Drug Tier 1, Tier 2, and Tier 3
4 Hereditary Angioedema Drug Market by Type
  1. 4.1 Hereditary Angioedema Drug Type Introduction
  2. 4.1.1 C1 Esterase Inhibitor
  3. 4.1.2 Kallikrein Inhibitor
  4. 4.1.3 Selective Bradykinin B2 Receptor Antagonist
  5. 4.2 Global Hereditary Angioedema Drug Sales by Type
  6. 4.2.1 Global Hereditary Angioedema Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hereditary Angioedema Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Hereditary Angioedema Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Hereditary Angioedema Drug Revenue by Type
  10. 4.3.1 Global Hereditary Angioedema Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hereditary Angioedema Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Hereditary Angioedema Drug Revenue Market Share by Type (2021-2032)
5 Hereditary Angioedema Drug Market by Application
  1. 5.1 Hereditary Angioedema Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Hereditary Angioedema Drug Sales by Application
  6. 5.2.1 Global Hereditary Angioedema Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hereditary Angioedema Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Hereditary Angioedema Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hereditary Angioedema Drug Revenue by Application
  10. 5.3.1 Global Hereditary Angioedema Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hereditary Angioedema Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Hereditary Angioedema Drug Revenue Market Share by Application (2021-2032)
6 Global Hereditary Angioedema Drug Sales by Region
  1. 6.1 Global Hereditary Angioedema Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hereditary Angioedema Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hereditary Angioedema Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Hereditary Angioedema Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hereditary Angioedema Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hereditary Angioedema Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hereditary Angioedema Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hereditary Angioedema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hereditary Angioedema Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hereditary Angioedema Drug Revenue by Region
  1. 7.1 Global Hereditary Angioedema Drug Revenue by Region
  2. 7.1.1 Global Hereditary Angioedema Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hereditary Angioedema Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Hereditary Angioedema Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Hereditary Angioedema Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hereditary Angioedema Drug Revenue (2021-2032)
  8. 7.2.2 North America Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hereditary Angioedema Drug Revenue (2021-2032)
  11. 7.3.2 Europe Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hereditary Angioedema Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hereditary Angioedema Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hereditary Angioedema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Hereditary Angioedema Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Pharming Group NV
  8. 8.2.1 Pharming Group NV Company Information
  9. 8.2.2 Pharming Group NV Business Overview
  10. 8.2.3 Pharming Group NV Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pharming Group NV Hereditary Angioedema Drug Product Portfolio
  12. 8.2.5 Pharming Group NV Recent Developments
  13. 8.3 Ionis Pharmaceuticals, Inc.
  14. 8.3.1 Ionis Pharmaceuticals, Inc. Company Information
  15. 8.3.2 Ionis Pharmaceuticals, Inc. Business Overview
  16. 8.3.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  18. 8.3.5 Ionis Pharmaceuticals, Inc. Recent Developments
  19. 8.4 IBio Inc.
  20. 8.4.1 IBio Inc. Company Information
  21. 8.4.2 IBio Inc. Business Overview
  22. 8.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 IBio Inc. Hereditary Angioedema Drug Product Portfolio
  24. 8.4.5 IBio Inc. Recent Developments
  25. 8.5 CSL Limited
  26. 8.5.1 CSL Limited Company Information
  27. 8.5.2 CSL Limited Business Overview
  28. 8.5.3 CSL Limited Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CSL Limited Hereditary Angioedema Drug Product Portfolio
  30. 8.5.5 CSL Limited Recent Developments
  31. 8.6 BioCryst Pharmaceuticals, Inc.
  32. 8.6.1 BioCryst Pharmaceuticals, Inc. Company Information
  33. 8.6.2 BioCryst Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  36. 8.6.5 BioCryst Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hereditary Angioedema Drug Value Chain Analysis
  2. 9.1.1 Hereditary Angioedema Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hereditary Angioedema Drug Production Mode & Process
  6. 9.2 Hereditary Angioedema Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hereditary Angioedema Drug Distributors
  9. 9.2.3 Hereditary Angioedema Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst